Literature DB >> 19218548

Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia.

Tamara Riedt1, Martin Ebinger, Helmut R Salih, Jürgen Tomiuk, Rupert Handgretinger, Lothar Kanz, Frank Grünebach, Claudia Lengerke.   

Abstract

Members of the caudal (cdx) family of homeobox proteins are essential regulators of embryonic blood development in zebrafish. Previously, we reported that the murine homologues (Cdx1, Cdx2, and Cdx4) affect formation and differentiation of embryonic stem cell (ESC)-derived hematopoietic progenitor cells. Consistent with the notion that embryonic pathways can reactivate during adult oncogenesis, recent studies suggest involvement of CDX2 in human acute myeloid leukemia (AML). Here we study CDX2 in healthy and leukemic human lymphoid cells, and show that a majority of leukemic samples display various degrees of aberrant CDX2 expression. Analysis of a cohort of 37 childhood acute lymphoblastic leukemia (ALL) patients treated in our hospital reveals that high CDX2 expression levels at diagnosis correlate with persistence of minimal residual disease (MRD) during the course of treatment. Thus, CDX2 expression levels may serve as a marker for adverse prognosis in pediatric ALL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19218548     DOI: 10.1182/blood-2008-12-196634

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states.

Authors:  Arvind Shakya; Jinsuk Kang; Jeffrey Chumley; Matthew A Williams; Dean Tantin
Journal:  J Biol Chem       Date:  2010-11-04       Impact factor: 5.157

3.  Modulation of Tcf3 repressor complex composition regulates cdx4 expression in zebrafish.

Authors:  Hyunju Ro; Igor B Dawid
Journal:  EMBO J       Date:  2011-06-10       Impact factor: 11.598

4.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.

Authors:  Zhong Wang; Masayuki Iwasaki; Francesca Ficara; Chenwei Lin; Christina Matheny; Stephen H K Wong; Kevin S Smith; Michael L Cleary
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

5.  miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies.

Authors:  Kang-Yu Lin; Xing-Ju Zhang; Dan-Dan Feng; Hua Zhang; Cheng-Wu Zeng; Bo-Wei Han; Ai-Dong Zhou; Liang-Hu Qu; Ling Xu; Yue-Qin Chen
Journal:  J Biol Chem       Date:  2011-09-08       Impact factor: 5.157

Review 6.  Beyond Hox: the role of ParaHox genes in normal and malignant hematopoiesis.

Authors:  Vijay P S Rawat; R Keith Humphries; Christian Buske
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis.

Authors:  Sumin Koo; Brian J Huntly; Yuan Wang; Jing Chen; Kristina Brumme; Brian Ball; Shannon L McKinney-Freeman; Akiko Yabuuchi; Claudia Scholl; Dimple Bansal; Leonard I Zon; Stefan Fröhling; George Q Daley; D Gary Gilliland; Thomas Mercher
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

8.  Among sinonasal tumors, CDX-2 immunoexpression is not restricted to intestinal-type adenocarcinomas.

Authors:  Matthew P Tilson; Gary L Gallia; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2013-07-12

Review 9.  Caudal genes in blood development and leukemia.

Authors:  Claudia Lengerke; George Q Daley
Journal:  Ann N Y Acad Sci       Date:  2012-08       Impact factor: 5.691

Review 10.  Autologous blood cell therapies from pluripotent stem cells.

Authors:  Claudia Lengerke; George Q Daley
Journal:  Blood Rev       Date:  2009-11-11       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.